Company / Operating Income per Share
Haemonetics Operating Income per Share History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
$4.40
FY2024
5-year range
$1.57 / $4.40
FY2020-FY2024
Trend
+37.1%
vs FY2023
Sector context
#44 of 149
Health Care
What the data says
At $4.40, Haemonetics's operating income per share ranks #44 of 149 in the Health Care sector. Operating Income per Share has increased for 3 consecutive years, from $1.57 in FY2021 to $4.40 in FY2024.
Based on SEC 10-K filings.
4.40 in FY2024 with a 5-year CAGR of +17.1%.
Improved from $3.03 to $4.40 over the past 2 years.
Health Care sector context is included.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- +40.9%
- 5-Year CAGR
- +17.1%
- 10-Year CAGR
- -
Sector benchmark
#44 of 149 in Health CareTop 30% of 149This company $4.40 Sector average $4.30
▼
+2.3% above sector average
Key checks
Key Insights
- Haemonetics's operating income per share has grown for 3 consecutive years.
- In FY2024, operating income per share increased 37.1% year-over-year.
- Ranks #44 out of 149 companies in the Health Care sector.
- Lowest operating income per share in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $4.40 | +37.1% |
| FY2023 | $3.21 | +5.7% |
| FY2022 | $3.03 | +93.0% |
| FY2021 | $1.57 | -10.1% |
| FY2020 | $1.75 | -12.3% |
| FY2019 | $1.99 | +24.8% |
| FY2018 | $1.60 | +45.0% |
| FY2017 | $1.10 | +394.0% |
| FY2016 | -$0.38 | +55.6% |
As of FY2024 · SEC 10-K · Updated Mar 28, 2026